A fixed-dose combination analgesic containing Tapentadol, a centrally-acting opioid analgesic with noradrenaline reuptake inhibition, and Paracetamol, a centrally-acting non-opioid analgesic and antipyretic. This combination provides synergistic pain relief for moderate to severe acute pain, targeting both opioid and non-opioid pathways, while potentially allowing for lower opioid doses.
Adult: One tablet (Tapentadol 50mg + Paracetamol 325mg) every 4-6 hours as needed for pain. The minimum effective dose should be used for the shortest duration. Maximum: 4 tablets in 24 hours (i.e., Tapentadol 200mg + Paracetamol 1300mg).
Note: Administer orally with or without food. Tablet should be swallowed whole with a glass of water. Do not crush, chew, or break. To minimize GI upset, take with food or milk. Do not consume alcohol.
This combination provides dual analgesic action. Tapentadol exerts its effect through two distinct mechanisms: 1) Agonist activity at the mu-opioid receptor (MOR), and 2) Inhibition of neuronal noradrenaline reuptake (NRI). Paracetamol's exact mechanism is not fully elucidated but is believed to involve central inhibition of prostaglandin synthesis, possibly via COX-2 and COX-3 inhibition, and modulation of the serotonergic and cannabinoid systems. The combination results in synergistic pain relief.
Pregnancy: Category C (US FDA). Not recommended during pregnancy, especially during labor, due to risk of neonatal respiratory depression. Use only if potential benefit justifies potential fetal risk. Chronic use may lead to neonatal withdrawal syndrome.
Driving: May impair mental and/or physical abilities required for driving or operating machinery. Patients should be cautioned not to drive or use machinery until they know how the medication affects them. Dizziness and somnolence are common.
| Other Opioids (e.g., Morphine, Codeine), Benzodiazepines (e.g., Alprazolam), Sedatives/Hypnotics (e.g., Zolpidem) | Additive CNS depression, respiratory depression, sedation, coma risk. | Major |
| Alcohol | Increased CNS depression and risk of hepatotoxicity from Paracetamol. | Major |
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Selegiline | Risk of serotonin syndrome, hyperpyrexia, excitation. Contraindicated. | Major |
| Serotonergic Drugs (SSRIs e.g., Sertraline, SNRIs e.g., Venlafaxine, TCAs, Triptans, Tramadol) | Increased risk of serotonin syndrome. | Major |
| Muscle Relaxants (e.g., Baclofen, Tizanidine) | Enhanced sedative and respiratory depressant effects. | Moderate |
| Anticholinergics (e.g., Atropine, Antihistamines like Diphenhydramine) | Increased risk of urinary retention, severe constipation, CNS depression. | Moderate |
| Antihypertensives, Diuretics | Potentiation of hypotensive effects. | Moderate |
| Warfarin and other Coumarin Anticoagulants | Paracetamol may potentiate anticoagulant effect, increasing INR; monitor closely. | Moderate |
| Enzyme Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | May reduce Tapentadol efficacy and increase risk of Paracetamol hepatotoxicity by inducing CYP enzymes. | Moderate |
| Probenecid | May decrease Paracetamol conjugation, increasing its levels. | Minor |
| Metoclopramide, Domperidone | May antagonize GI effects of Tapentadol; efficacy may be reduced. | Minor |